Recruiting

Vimseltinib

Sponsor:

Deciphera Pharmaceuticals, LLC

Code:

NCT07075471

Conditions

Tenosynovial Giant Cell Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT.

This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Conditions

Tenosynovial Giant Cell Tumor

Study ID

NCT07075471

Start date

Sep 3, 2025

Status verified date

Jul, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Sep, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Diagnosis of TGCT according to medical records
2. Prescribed vimseltinib per the approved label requirements, OR The decision to receive vimseltinib has been made but treatment has not yet been initiated.
3. Has provided informed consent and medical records release

Exclusion Criteria:

1\. Participant is active in an interventional clinical trial of vimseltinib

Study Design

Enrollment

100 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Duration of Vimseltinib Treatment [ Time Frame: Baseline up to 12 months ]
  • Time to Discontinuation of Vimseltinib [ Time Frame: Baseline to Discontinuation (Estimated up to 12 months) ]

Central Contacts and Locations

Central contacts

Clinical Team

888-724-3274clinicaltrials@deciphera.com

Locations

Synexus Clinical Research, US INC

Recruiting

Wilmington, North Carolina, United States, 28401

Contacts

888-581-9246

More Information

Sponsor

Deciphera Pharmaceuticals, LLC

Last update posted

Jul 27, 2026

Last verified

Jul, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Deciphera Pharmaceuticals, LLC on 2026-07-27.